Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29745776 | 0.85 | LTA4H (0.31) | LTA4H | |
| SCHEMBL18473590 | 0.82 | — | — | |
| SCHEMBL29745774 | 0.82 | CYP3A4 (0.32) | ALDH1A1LMNATP53SMN1; SMN2 | |
| SCHEMBL2233775 | 0.79 | TDP1 (0.39) | TSHRALDH1A1LMNATP53SMN1; SMN2 | |
| SCHEMBL13136018 | 0.74 | LMNA (0.30) | LMNA | |
| SCHEMBL24718701 | 0.73 | CYP3A4 (0.31) | — | |
| SCHEMBL17828677 | 0.72 | PGR (0.31) | — | |
| SCHEMBL17828674 | 0.71 | PGR (0.30) | — | |
| SCHEMBL18840105 | 0.71 | PGR (0.30) | — | |
| SCHEMBL911476 | 0.71 | CYP3A4 (0.39) | TSHRLTA4HALDH1A1TP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220241764-A1 | CATALYST COMPOSITION AND PROCESS FOR OLIGOMERIZATION OF ETHYLENE | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2022-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220241764-A1 | CATALYST COMPOSITION AND PROCESS FOR OLIGOMERIZATION OF ETHYLENE | XRN2, XRCC6, TRRAP | TSHR 105/4885LTA4H 3117/4885ALDH1A1 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.